[A case of simultaneous double cancers with multiple liver metastases responding to S-1+CPT-11].
The patient was a 70-year-old male with advanced cancers of stomach and rectum and multiple metastatic hepatic tumors. No resectability was detected. The origin of metastatic hepatic tumors was unknown, so the combination of S- / 1 and CPT-11 as a treatment regimen was selected. S-1, 80 mg m(2), was administered on 14 consecutive days followed / by a 14-day rest period, and CPT-11, 100 mg/m(2), was administered on day 1 and day 15. One cycle was defined as 4 weeks, and cycles were repeated. CR was achieved as long as metastatic hepatic tumors after completion of 5 cycles. When we encounter a case of simultaneous double cancers with metastatic sites which has no respectability, generally speaking, it is difficult to determine the strategy for chemotherapy. This case suggests that the combination of S-1 and CPT-11 may be an effective regimen for the treatment of simultaneous advanced cancers of stomach and rectum with multiple hepatic metastases.
Iizuka
Toshiro
T
Dept. of Gastroenterology, Toranomon Hospital, Japan.
Hirano
Naoki
N
Kikuchi
Daisuke
D
Hoteya
Shu
S
Yahagi
Naohisa
N
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001706:Biopsy; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen / Q000097:blood; D004338:Drug Combinations; D016099:Endoscopy, Gastrointestinal; D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000097:blood / Q000188:drug therapy* / Q000473:pathology*; D010094:Oxonic Acid / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D002272:Carcinoembryonic Antigen; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin